View in EDS

Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells.

Saved in:
Bibliographic Details
Title: Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells.
Authors: Zaffran I; Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel., Landolina N; Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel., Gaur P; Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel., Rovis TL; Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia., Jonjic S; Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia., Mandelboim O; The Lautenberg Center for General and Tumor Immunology, The Hebrew University Hadassah Medical School, IMRIC, Jerusalem, Israel., Singer BB; Institute of Anatomy, Medical Faculty, University Duisburg-Essen, Essen, Germany., Levi-Schaffer F; Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. francescal@ekmd.huji.ac.il.
Source: Cancer gene therapy [Cancer Gene Ther] 2022 Nov; Vol. 29 (11), pp. 1676-1685. Date of Electronic Publication: 2022 Jun 09.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5500 (Electronic) Linking ISSN: 09291903 NLM ISO Abbreviation: Cancer Gene Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5500
DOI:10.1038/s41417-022-00486-x